News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
The Business Journals Deals and strategy
French pharmaceutical giant Sanofi is laying off 229 employees from Blueprint Medicines and consolidating operations in Cambridge. This move follows Sanofi's $9.1 billion acquisition of Blueprint Medicines. The layoffs and office closures are part of Sanofi's efforts to integrate the acquired workforce and operations.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sanofi is reorganizing its Executive Committee, effective September 1, 2026, to expand the finance function's responsibilities and consolidate its senior leadership. The finance division will now oversee enterprise business services, Global Partnering, Business Development, and M&A, with François Roger remaining as EVP of Finance. …
The Manufacturers Life Insurance Company significantly reduced its stake in Sanofi by 58.9% in the first quarter of 2026, selling over 33,000 shares. Despite this, other institutional investors like Assetmark, QRG Capital Management, and Evergreen Capital Management increased their holdings in the pharmaceutical company. …
Analysts have cut Sanofi's average 12-month price target from $50.6 to $50, with individual forecasts ranging from $45 to $57 per share. Based on the Aug. 7 closing price, this new target suggests a potential upside of approximately 15%. The consensus rating from seven …
It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …
Sanofi received European Commission approval to expand the MenQuadfi meningococcal vaccine's use to infants as young as six weeks old, covering a high-risk population. Despite this and a recent share buyback, Sanofi's stock performance has been subdued. The company's valuation narrative suggests it is …
The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as 6 weeks, expanding protection against invasive meningococcal disease. This decision is significant for hearing healthcare professionals, as the disease is a leading cause of acquired sensorineural hearing loss in …
The NAACP and Sanofi have launched an interactive health equity map called "Black Communities' Health: In Plain Sight." This tool uses data from nearly 23,000 residents across 47 states, D.C., and Puerto Rico to highlight health disparities at the ZIP-code level, focusing on access …
Sanofi has suspended a phase 2 trial of its monoclonal antibody SAR445399 for non-cystic fibrosis bronchiectasis. The decision stems from a company-wide portfolio review under new CEO Belén Garijo, not safety concerns. This pause follows other recent pipeline adjustments as Sanofi reassesses its late-stage …
Former Sanofi, CVS Health, and McKesson Executive Improve Specialty Drug Access, Affordability and Patient Support NEW YORK, August 06, 2026--(BUSINESS WIRE)--Leap, the healthcare company making specialty medicine more affordable and easier to access, today announced the appointment of Christine Hummel as Senior Vice President …
Sanofi has paused a Phase 2 study for an investigational antibody, SAR445399, in non-cystic fibrosis bronchiectasis as part of new CEO Belén Garijo’s "rigorous portfolio prioritization" process. This decision is based on strategic business reasons rather than the asset's safety or efficacy. The company …
Sanofi has been asked by the National Advertising Division (NAD) to alter or remove specific advertising claims for its drug Dupixent, following a challenge by Galderma. This development is part of an ongoing advertising dispute between the two pharmaceutical companies, which are competing for …
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding …
Antipodes Partners published its "Antipodes Global Strategy" second-quarter 2026 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. The second quarter of 2026 delivered one of the strongest equity market recoveries …
Expedition Therapeutics, backed by Sanofi, has raised an oversubscribed $115 million in Series B financing to propel its lead DPP1 inhibitor, EXPD-101, through phase 2 trials for chronic obstructive pulmonary disease (COPD). This funding follows a $165 million Series A in October 2025 and …
Sanofi has halted a phase 2 trial for SAR445399, a monoclonal antibody for non-cystic fibrosis bronchiectasis, citing "strategic business reasons" following a company-wide portfolio review. This decision comes amidst a challenging period for Sanofi, marked by recent trial failures and the new CEO's efforts …
Sanofi's MenQuadfi vaccine has
Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, …
[Sanofi building on New York Ave in Framingham, MA, USA] JHVEPhoto Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) received [https://seekingalpha.com/pr/20605048-press-release-sanofi-s-menquadfi-approved-in-the-eu-for-use-in-infants-from-age-six-weeks] European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W …
The European Commission has approved an extension of the indication for Sanofi's MenQuadfi vaccine to include infants from six weeks of age, protecting against invasive meningococcal disease caused by serogroups A, C, W, and Y. This expanded approval, supported by the MET58 pivotal study, …
Sanofi has halted the development of amlitelimab for atopic dermatitis after a pipeline review indicated no significant improvement over existing treatments. This decision removes a key immunology asset from its portfolio and raises questions for investors regarding the reallocation of research capital. The market …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi (ENXTPA:SAN) drew fresh investor attention after reporting €1,031 million of intangible asset impairments for Q2 2026, along with completing a €1,009 million …
Sanofi's new CEO, Belén Garijo, aims to strengthen the company's partnership with Regeneron, expanding their alliance and increasing transparency. This comes as Sanofi prepares for Dupixent's patent cliff by focusing on business development and M&A. Separately, Apnimed's IPO surpassed expectations, becoming the 15th "upsized" …
Sanofi's new CEO, Belén Garijo, has initiated an accelerated transformation roadmap focused on commercial strengths and R&D pipeline improvements. The company aims to diversify its portfolio and reduce reliance on top-selling Dupixent by prioritizing new product growth and strategically assessing its pipeline, including discontinuing …
Sanofi's shares dropped sharply after its new CEO, Belen Garijo, admitted the company faces challenges in filling its drug pipeline, necessitating increased spending and potential deals. Garijo announced a revamp of the research-and-development operations and an intention to intensify dealmaking to improve growth prospects. …
Sanofi's new CEO, Belén Garijo, is undertaking a rigorous assessment of the company's late-stage pipeline, leading to the discontinuation of several previously touted drug candidates. Her strategy focuses on investing where science is strongest and unmet medical needs are greatest, while also considering acquisitions …
Rapport financier semestriel 2026 de Sanofi Paris, le 30 juillet 2026. Sanofi annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son rapport financier semestriel au 30 juin 2026. Le rapport financier semestriel peut être …
Sanofi is discontinuing the development of two more R&D programs, anti-IL33 antibody itepekimab and TNF inhibitor balinatunfib, as part of a significant R&D clear-out under new CEO Belén Garijo. This follows the recent termination of amlitelimab for atopic dermatitis, marking a substantial shift in …
Key Points Interested in Sanofi? Here are five stocks we like better. Sanofi raised its 2026 outlook after second-quarter sales rose 17.8% to €11.6 billion and business EPS increased 33.3%, driven by Dupixent, new medicines and cost discipline. Dupixent quarterly sales surpassed €5 billion, …
Sanofi's new CEO, Belén Garijo, is implementing a more rigorous approach to pipeline prioritization and Phase 3 go/no-go decisions, focusing on assets with strong scientific merit and long-term value. This strategy follows the discontinuation of several programs, including most amlitelimab trials, and aims to …
July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Shares rose nearly 5% before the bell. Here are the …
Search by ticker symbol or company name and select a result to open its chart.